Background Identifying simple, low-cost and scalable means of supporting lifestyle change and medication adherence for patients following a cardiovascular (CV) event is important. Objective The TEXTMEDS (TEXT messages to improve MEDication adherence and Secondary prevention) study aims to investigate whether a cardiac education and support programme sent via mobile phone text message improves medication adherence and risk factor levels in patients following an acute coronary syndrome (ACS). Study design A single-blind, multicentre, randomised clinical trial of 1400 patients after an ACS with 12 months follow-up. The intervention group will receive multiple weekly text messages that provide information, motivation, support to adhere to medications, quit smoking (if relevant) and recommendations for healthy diet and exercise. The primary endpoint is the percentage of patients who are adherent to cardioprotective medications and the key secondary outcomes are mean systolic blood pressure (BP) and low-density lipoprotein cholesterol. Secondary outcomes will also include total cholesterol, mean diastolic BP, the percentage of participants who are adherent to each cardioprotective medication class, the percentage of participants who achieve target levels of CV risk factors, major vascular events, hospital readmissions and all-cause mortality. The study will be augmented by formal economic and process evaluations to assess acceptability, utility and cost-effectiveness. Summary The study will provide multicentre randomised trial evidence of the effects of a text message-based programme on cardioprotective medication adherence and levels of CV risk factors. Ethics and dissemination Primary ethics approval was received from Western Sydney Local Health District Human Research Ethics Committee (HREC2012/12/4.1 (3648) AU RED HREC/13/WMEAD/15). Results will be disseminated via peer-reviewed publications and presentations at international conferences. Trial registration number ACTRN12613000793718; Pre-results.

https://bmjopen.bmj.com/content/bmjopen/8/1/e019463.full.pdf

TEXT messages to improve MEDication adherence and secondary prevention (TEXTMEDS) after acute coronary syndrome: a randomised clinical trial protocol

Clinical guidelines recommend peri-cardioversion anticoagulation in patients with atrial fibrillation (AF). We performed a systematic review and meta-analysis to compare the safety and efficacy of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients with AF undergoing cardioversion. We searched CENTRAL, MEDLINE, and EMBASE for randomized controlled trials (RCTs) and observational studies comparing DOACs to VKAs in patients undergoing cardioversion for AF. We performed title, abstract, and full-text screening, data extraction, and risk of bias evaluation independently and in duplicate. We pooled data using a random effects model and evaluated the overall quality of evidence using Grading of Recommendations Assessment, Development and Evaluation. We identified three eligible RCTs (n = 5203) and 21 observational studies (n = 11,855). The three RCTs and four observational studies were at low risk of bias. In RCTs (mean follow-up, 30 days), thromboembolic events occurred in 0.18% of patients receiving DOACs, as compared with 0.55% receiving VKAs (relative risk [RR] 0.40, 95% CI [0.13, 1.24], moderate quality). Major bleeding occurred in 0.42% of patients receiving DOACs as compared with 0.64% receiving VKAs (RR 0.62, 95% CI [0.28, 1.35], moderate quality), and death occurred in 0.28% of patients receiving DOACs as compared with 0.38% receiving VKAs (RR 0.70, 95% CI [0.23, 2.10], low quality). Confidence in the estimates of effect for observational studies was very low. DOACs peri-cardioversion in patients with AF appears safe from both a bleeding and thromboembolic risk perspective. Available evidence supports the use of DOACs as standard of care peri-cardioversion in patients with AF.

Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients Undergoing Cardioversion for Atrial Fibrillation: a Systematic Review and Meta-analysis

Despite guidelines advocating routine engagement with proven secondary prevention strategies, current uptake and access remain suboptimal. Australian registries of acute coronary syndrome have predominantly focused on inpatient care and have highlighted under-referral to cardiac rehabilitation, gaps in medication prescription and limited commencement of lifestyle change before discharge from hospital. Opportunities to improve equity, access and uptake of secondary prevention include better transition between acute and primary care, systematic delivery of prevention in primary care, workforce strengthening and embracing new technologies. Adopting a structured framework for delivery of secondary prevention in primary care will enhance continuity of care and improve coordination of services after acute coronary syndrome.

/pdf/the-transition-from-hospital-to-primary-care-for-patients-4mq9uky09v.pdf

The transition from hospital to primary care for patients with acute coronary syndrome: insights from registry data.

Use of Secondary PreventionMedications in Patients Following Admission with Acute Coronary Syndrome in Australia—The CONCORDANCE Study C. Chow1,2,∗, I. Ranasinghe1,3, A. Blenkhorn4, K. Alford5, M. Ilton6, A. Patel 1 1 The George Institute for Global Health, University of Sydney, Australia 2 Department of Cardiology, Westmead Hospital, Australia 3 Department of Cardiology, Concord Hospital, Australia 4 Lismore Base Hospital, Australia 5 Port Macquarie Base Hospital, Australia 6 Royal Darwin Hospital, Australia

A. Blenkhorn

Papers

Use of Secondary Prevention Medications in Patients Following Admission with Acute Coronary Syndrome in Australia—The CONCORDANCE Study

The Incidence of Left Atrial Appendage Thrombus in Warfarin Versus Noacs Prior to Transoesophageal Echocardiogram Guided Cardioversion